Skip to Content
Merck
CN

357M-1

TCL1 (MRQ-7) Mouse Monoclonal Antibody

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
MRQ-7, monoclonal
Application:
IHC (p)
Citations:
10
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

mouse

Quality Segment

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

MRQ-7, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (357M-14), vial of 0.5 mL concentrate (357M-15), bottle of 1.0 mL predilute (357M-17), vial of 1.0 mL concentrate (357M-16), bottle of 7.0 mL predilute (357M-18)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

isotype

IgG

control

B-cell lymphoma, tonsil

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic, nuclear

Gene Information

human ... TCL1A(8115)

General description

T-cell leukemia/lymphoma protein 1 (TCL1, TCL1A, p14TCL1) is a 14 kDa product of the TCL1 gene that is involved in T-cell prolymphocytic leukemia (T-PLL). TCL1 protein is normally found in the nucleus and cytoplasm of lymphoid lineage cells during early embryogenesis. Chromosomal translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 binds to a novel site in the pleckstrin homology (PH) domain, resulting in activation and nuclear translocation of Akt by overexpressed TCL1 which may promote an anti-apoptotic response; this may normally serve to promote growth during development but may lead to malignancy when TCL1 is overexpressed. TCL1 is expressed in differentiated B-cells under both reactive and neoplastic conditions, antigen committed B-cells, and in germinal center B-cells. TCL1 is down-regulated in the latest stage of B-cell differentiation. TCL1 is overexpressed in Burkitt lymphoma, the majority of AIDS-related non-Hodgkin lymphoma-designated immunoblastic plasmacytoid lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and primary cutaneous B-cell lymphoma. Therefore, the most useful application of anti-TCL1 is the discrimination of B-cell lymphomas from T-cell lymphomas, CD30+ anaplastic large cell lymphomas, multiple myeloma, and marginal zone B-cell lymphoma.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Analysis Note


IVD

IVD

IVD

RUO

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
TCL1 Positive Control Slides, Product No. 357S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

Try our Product Selector Tool to narrow your options


Regulatory Information

监管及禁止进口产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library







Global Trade Item Number

SKUGTIN
357M-180841683138419
357M-16-RUO04061836533588
357M-170841683138402
357M-140841683138372
357M-150841683138389
357M-160841683138396